 |
 |
As I indicated, this was an oral presentation at the June ENS meeting in Munich, not yet published in a refereed journal: "Dr. P. H. Kraus and her colleagues at the University of Bochum (Germany) collaborated with ASTA Medica personnel in a study of a new atypic neuroleptic, prothipendyl. Comparable to clozapine in benefits to patients in controlling agitation and sleep disturbances, unlike clozapine, this new drug does not cause agranulocytosis which, though infrequently occurring, is dangerous enough to require weekly blood tests, greatly increasing the cost of clozapine. This was an open-label study in 12 tremor-dominant patients, who were given up to 90mg per day. In addition to the above problems, tremors were also reduced with no worsening of akinesia. This promising drug, they concluded, deserves appropriate double-blind studies." Regards, Joe J. R. Bruman (818) 789-3694 3527 Cody Road Sherman Oaks CA 91403 On Mon, 25 Sep 1995, Lloyd Stewart wrote: > > > > > Date: Sat, 23 Sep 1995 10:00:45 -0700 > From: "J.R. Bruman" <[log in to unmask]> > Subject: Current Science Reviews > > > European Neurological Society Meeting Highlights: > > J. R. Bruman (818) 789-3694 > 3527 Cody Road > Sherman Oaks CA 91403 > > Dear Joe This is excellent, especially 'the neuroleptic prothipendyl is > comparable to clozapine in benefit, without the danger of anemia' and would be > pleased to hear more, but you have not given the reference, and prothipendyl > is not in Australia as far as I know, perhaps it is a trade name. > I would like to keep my bone marrow in one piece and have both mobility and a > relaxed mind, but my therapeutic window is not very wide, and new options are > good for morale if nothing else. So I would be grateful for more info. >